| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | -0.021 | 0.6 |
| mRNA | Obatoclax Mesylate | CTRPv2 | pan-cancer | AAC | 0.019 | 0.6 |
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | 0.021 | 0.6 |
| mRNA | AZD1480 | CTRPv2 | pan-cancer | AAC | -0.03 | 0.6 |
| mRNA | PL-DI | CTRPv2 | pan-cancer | AAC | -0.018 | 0.6 |
| mRNA | prima-1 | CTRPv2 | pan-cancer | AAC | -0.018 | 0.6 |
| mRNA | bafilomycin A1 | CTRPv2 | pan-cancer | AAC | -0.078 | 0.6 |
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | -0.018 | 0.6 |
| mRNA | selumetinib:BRD-A02303741 (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.019 | 0.6 |
| mRNA | BRD8958 | CTRPv2 | pan-cancer | AAC | -0.022 | 0.6 |